Repurposing of Plasminogen: An Orphan Medicinal Product Suitable for SARS-CoV-2 Inhalable Therapeutics
The SARS-CoV-2 infection is associated with pulmonary coagulopathy, which determines the deposition of fibrin in the air spaces and lung parenchyma. The resulting lung lesions compromise patient pulmonary function and increase mortality, or end in permanent lung damage for those who have recovered f...
Main Authors: | Anna Maria Piras, Ylenia Zambito, Maurizio Lugli, Baldassare Ferro, Paolo Roncucci, Filippo Mori, Alfonso Salvatore, Ester Ascione, Marta Bellini, Roberto Crea |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-11-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/13/12/425 |
Similar Items
-
Single measurement of plasminogen activator inhibitor-1 in sepsis: is it useful for evaluating the severity or prognosis of sepsis?
by: Kansuke Koyama, et al.
Published: (2017-11-01) -
Perfluorochemical‐facilitated plasminogen activator delivery to the airways: A novel treatment for inhalational smoke‐induced acute lung injury
by: Marla R. Wolfson, et al.
Published: (2020-03-01) -
Lack of durable protection against cotton smoke-induced acute lung injury in sheep by nebulized single chain urokinase plasminogen activator or tissue plasminogen activator
by: Satoshi Fukuda, et al.
Published: (2018-06-01) -
Plasminogen Receptors and Fibrinolysis
by: Lindsey A. Miles, et al.
Published: (2021-02-01) -
Characterization of plasmin, plasminogen and plasminogen activator in goat milk
by: F. Polidori, et al.
Published: (2011-03-01)